Biomarkers for Cardiovascular Drug Development: JACC State-of-the-Art Review
1. 系统已在2026-03-07 15:28:59对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
A Aimo, J Butler, L De Michieli, G Mendieta, F Zannad…
JACC, 2026
Elsevier
Circulating and urinary laboratory biomarkers are central to cardiovascular, kidney, and metabolic drug development, and they support diagnosis, risk stratification, dose finding, safety monitoring, and, in selected settings, endpoint definition. Yet only a few materially shape trial design or regulatory decisions, and still fewer meet stringent criteria for surrogate endpoints. This review proposes a context-of-use framework in which circulating biomarkers are assessed along 2 converging “evidence lanes”: analytical readiness and clinical or …
